John Parkinson

"The measles outbreak that is currently happening in Texas and New Mexico is occurring in an area of the states that have very high anti-vaccine sentiments," Tan said.

"Vaccines are our absolute best defense for protecting people of all ages against many serious infectious diseases," Tan said in a statement as president of IDSA.

This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.

This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.

In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).

A look into CDC numbers for increasing pertussis cases in the United States, along with commentary from our editor-in-chief, Tina Tan, MD, FAAP, FIDSA, FPIDS.

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

A retracted paper that erroneously claimed the measles, mumps and rubella (MMR) vaccine caused autism has repercussions still being felt today around topics such as vaccination, misinformation and disinformation, and measles incidence rates.

In the final installment of our RSV Roundtable video series, our panel breaks down the importance of discussing new immunizations with patients now, and how crucial they will be in future RSV seasons.

Biopharmaceutical company, Invivyd, made the request to the FDA for its investigational antibody, VYD222.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

In a large observational study, significant information was obtained about protection against acute infection and disease severity in this age group.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

The 2023 changes include vaccines for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.